Ultrasonography, Computed Tomography and Magnetic Resonance Imaging of Hepatocellular Carcinoma: Toward Improved Treatment Decisions

Detection, characterization, staging, and treatment monitoring are major roles in imaging diagnosis in liver cancers. Contrast-enhanced ultrasonography (CEUS) using microbubble contrast agents has expanded the role of US in the detection and diagnosis of liver nodules in patients at high risk of hepatocellular carcinoma (HCC). CEUS provides an accurate differentiation between benign and malignant liver nodules, which is critical for adequate management of HCC and is also useful for guidance of percutaneous local therapy of HCC and postprocedure monitoring of the therapeutic response. The technology of multidetector-row computed tomography (MDCT) has increased spatial and temporal resolutions of computed tomography (CT). It has made possible a more precise evaluation of the hemodynamics of liver tumor, and the diagnostic accuracy of dynamic MDCT has improved. Perfusion CT can measure tissue perfusion parameters quantitatively and can assess segmental hepatic function. Dynamic MDCT with high spatial and temporal resolution enables us to reconstruct 3- and 4-dimensional imaging, which is very useful for pretreatment evaluation. Dual-energy CT makes possible the differentiation of materials and tissues in images obtained based on the differences in iodine and water densities. Monochromatic images, which can be reconstructed by dual-energy CT data, provide some improvement in contrast and show a higher contrast-to-noise ratio for hypervascular HCCs. Dynamic magnetic resonance imaging with fast imaging sequence of 3-dimensional Fourier transformation T1-weighted gradient echo and nonspecific contrast medium can show high detection sensitivity of hypervascular HCC. However, the hepatic tissue-specific contrast medium, gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid, has become an essential contrast medium for liver imaging because of its higher diagnostic ability. It may replace CT during hepatic arteriography and during arterioportography.

[1]  H. Genant,et al.  Quantitative bone mineral analysis using dual energy computed tomography. , 1977, Investigative radiology.

[2]  R. Brooks A Quantitative Theory of the Hounsfield Unit and Its Application to Dual Energy Scanning , 1977, Journal of computer assisted tomography.

[3]  T J Brady,et al.  Ferrite particles: a superparamagnetic MR contrast agent for enhanced detection of liver carcinoma. , 1987, Radiology.

[4]  D. D. Stark,et al.  Iron oxide-enhanced MR imaging of the liver and spleen: review of the first 5 years. , 1990, AJR. American journal of roentgenology.

[5]  O. Matsui,et al.  Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. , 1991, Radiology.

[6]  R. Brasch New directions in the development of MR imaging contrast media. , 1992, Radiology.

[7]  M. Taupitz,et al.  Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. , 1995, Radiology.

[8]  R. Murakami,et al.  Hepatocellular carcinoma in cirrhotic livers: detection with unenhanced and iron oxide-enhanced MR imaging. , 1995, Radiology.

[9]  T Berns,et al.  Clinical results with Resovist: a phase 2 clinical trial. , 1995, Radiology.

[10]  A. Herneth,et al.  Hepatic perfusion after liver transplantation: noninvasive measurement with dynamic single-section CT. , 1998, Radiology.

[11]  O. Matsui,et al.  Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. , 1999, AJR. American journal of roentgenology.

[12]  R. Craen,et al.  Dynamic CT measurement of cerebral blood flow: a validation study. , 1999, AJNR. American journal of neuroradiology.

[13]  T. Murakami,et al.  Superparamagnetic iron oxide–enhanced magnetic resonance images of hepatocellular carcinoma: Correlation with histological grading , 2000, Hepatology.

[14]  F Frouin,et al.  Early changes in liver perfusion caused by occult metastases in rats: detection with quantitative CT. , 2001, Radiology.

[15]  O. Matsui,et al.  Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. , 2002, Radiology.

[16]  Takamichi Murakami,et al.  Multi-detector row helical CT angiography of hepatic vessels: depiction with dual-arterial phase acquisition during single breath hold. , 2002, Radiology.

[17]  T. Murakami,et al.  Detection of Hypervascular Hepatocellular Carcinoma: Comparison of SPIO-enhanced MRI With Dynamic Helical CT , 2002, Journal of computer assisted tomography.

[18]  S. Kumano,et al.  Detection of hepatocellular carcinoma: comparison of dynamic MR imaging with dynamic double arterial phase helical CT. , 2003, AJR. American journal of roentgenology.

[19]  M. Bellin,et al.  Currently used non-specific extracellular MR contrast media , 2003, European Radiology.

[20]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[21]  P. Burns,et al.  Blood flow patterns in focal liver lesions at microbubble-enhanced US. , 2004, Radiographics : a review publication of the Radiological Society of North America, Inc.

[22]  K. Abe,et al.  Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. , 2005, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.

[23]  Takeshi Nakaura,et al.  Abdominal CT with low tube voltage: preliminary observations about radiation dose, contrast enhancement, image quality, and noise. , 2005, Radiology.

[24]  Young Kon Kim,et al.  Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detector row CT. , 2006, Radiology.

[25]  P. Burns,et al.  Microbubble Contrast for Radiological Imaging: 1. Principles , 2006, Ultrasound quarterly.

[26]  T. Murakami,et al.  Determining the Optimal Timing for Early Arterial Phase Hepatic CT Imaging by Measuring Abdominal Aortic Enhancement in Variable Contrast Injection Protocols , 2006, Journal of computer assisted tomography.

[27]  Y. Takeda,et al.  Assessment of the severity of liver disease and fibrotic change: the usefulness of hepatic CT perfusion imaging. , 2006, Oncology reports.

[28]  Y. Takeda,et al.  Quantitative Tissue Blood Flow Measurement of the Liver Parenchyma: Comparison Between Xenon CT and Perfusion CT , 2007, Digestive Diseases and Sciences.

[29]  Zhuang-Wei Xiao,et al.  Peripheral pulmonary nodules: Relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and VEGF expression , 2008, BMC Cancer.

[30]  T. Murakami,et al.  Potential of Gadolinium-ethoxybenzyl-diethylenetriamine Pentaacetic Acid (Gd-EOB-DTPA) for Differential Diagnosis of Nonalcoholic Steatohepatitis and Fatty Liver in Rats Using Magnetic Resonance Imaging , 2007, Investigative radiology.

[31]  Fuminori Moriyasu,et al.  Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. , 2007, Ultrasound in medicine & biology.

[32]  Young Kon Kim,et al.  Usefulness of Combining Sequentially Acquired Gadobenate Dimeglumine-Enhanced Magnetic Resonance Imaging and Resovist-Enhanced Magnetic Resonance Imaging for the Detection of Hepatocellular Carcinoma: Comparison With Computed Tomography Hepatic Arteriography and Computed Tomography Arterioportograph , 2007, Journal of computer assisted tomography.

[33]  T. Kim,et al.  Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation. , 2007, Radiology.

[34]  H. Fukuda,et al.  Multidetector helical CT plus superparamagnetic iron oxide-enhanced MR imaging for focal hepatic lesions in cirrhotic liver: a comparison with multi-phase CT during hepatic arteriography. , 2007, European journal of radiology.

[35]  T. Murakami,et al.  Hypervascular hepatocellular carcinoma: Combined dynamic MDCT and SPIO‐enhanced MRI versus combined CTHA and CTAP , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[36]  Masatoshi Kudo,et al.  Radiofrequency ablation of hepatocellular carcinoma: value of virtual CT sonography with magnetic navigation. , 2008, AJR. American journal of roentgenology.

[37]  Ehsan Samei,et al.  Hypervascular liver tumors: low tube voltage, high tube current multi-detector row CT for enhanced detection--phantom study. , 2008, Radiology.

[38]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[39]  F. Fazio,et al.  Hepatocellular carcinoma in cirrhotic liver disease: functional computed tomography with perfusion imaging in the assessment of tumor vascularization. , 2008, Academic radiology.

[40]  B. Yeh,et al.  Dual-energy and low-kVp CT in the abdomen. , 2009, AJR. American journal of roentgenology.

[41]  Kouichi Itoh,et al.  Efficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial. , 2009, AJR. American journal of roentgenology.

[42]  M. Okada,et al.  Focal liver tumors: characterization with 3D perflubutane microbubble contrast agent-enhanced US versus 3D contrast-enhanced multidetector CT. , 2009, Radiology.

[43]  Ehsan Samei,et al.  Hypervascular liver tumors: low tube voltage, high tube current multidetector CT during late hepatic arterial phase for detection--initial clinical experience. , 2009, Radiology.

[44]  Masahiro Okada,et al.  Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow , 2010, European Radiology.

[45]  Masahiro Okada,et al.  Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate‐ and ferucarbotran‐enhanced magnetic resonance imaging , 2010, Journal of magnetic resonance imaging : JMRI.

[46]  Tae Kyoung Kim,et al.  Hypervascular liver masses on contrast-enhanced ultrasound: the importance of washout. , 2010, AJR. American journal of roentgenology.

[47]  Role of Sonazoid-enhanced three-dimensional ultrasonography in the evaluation of percutaneous radiofrequency ablation of hepatocellular carcinoma. , 2010, European journal of radiology.

[48]  C. Catalano,et al.  Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis. , 2010, Radiology.

[49]  H. C. Yu,et al.  Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine. , 2010, The British journal of radiology.

[50]  Kinuyo Hatanaka,et al.  Double-Contrast Ultrasound: A Novel Surveillance Tool for Hepatocellular Carcinoma , 2011, The American Journal of Gastroenterology.

[51]  K. Lee,et al.  Hepatocellular nodules in liver cirrhosis: contrast-enhanced ultrasound , 2011, Abdominal Imaging.

[52]  Masahiro Okada,et al.  Hepatocellular nodules in liver cirrhosis: state of the art CT evaluation (perfusion CT/volume helical shuttle scan/dual-energy CT, etc.) , 2011, Abdominal Imaging.

[53]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[54]  S. Kumano,et al.  Optimal scanning protocol of arterial dominant phase for hypervascular hepatocellular carcinoma with gadolinium‐ethoxybenzyl‐diethylenetriamine pentaacetic acid‐enhanced MR , 2011, Journal of magnetic resonance imaging : JMRI.

[55]  真広 岡田 Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging , 2011 .